IcatibantPrescription medicine
Icatibant blocks the bradykinin B2 receptor. Its established clinical context is the treatment of attacks of hereditary angioedema associated with C1-inhibitor deficiency.
What is Icatibant?
Icatibant is a bradykinin B2-receptor antagonist used to treat hereditary-angioedema attacks associated with C1-inhibitor deficiency.
How it works
Blocking the B2 receptor prevents bradykinin from triggering the vascular effects that allow fluid to enter surrounding tissues.
Effects studied
Time to symptom relief during attacks
The checked EMA overview reports earlier symptom relief with icatibant than comparator treatment in assessed studies. This is treatment of an attack, not removal of the inherited tendency to attacks. 3
Evidence: Regulator-assessed clinical comparisons
What does the evidence show?
The EMA public assessment describes clinical comparisons and EU authorisation. The regulator’s overview was checked for this introduction; the full prescribing document was not re-audited.
The signal behind the swelling
When too much bradykinin reaches its receptors, blood vessels can allow fluid to move into surrounding tissues. Icatibant prevents bradykinin from activating the B2 receptor. That explains why the diagnosis matters: swelling driven by another mechanism may require a different approach.
What the studies asked
Clinical comparisons examined how quickly symptoms of hereditary-angioedema attacks improved. The EMA overview reports earlier relief with icatibant than with comparator treatment in the assessed studies. Time to relief is an attack-level outcome; it does not mean the inherited tendency to attacks has disappeared. 3
Treatment and emergency planning
Some patients or caregivers can administer the prescribed medicine after training. Throat swelling remains potentially life-threatening and needs urgent medical attention, even when a person has access to treatment. A drug description cannot replace the individual emergency plan made with the treating team.
Injection-site reactions and eligibility
Reactions around the injection site are common. The EMA record also makes clear that eligibility and dosing differ by age and weight. The current product information provides those instructions. This introduction explains the mechanism and evidence; it does not provide a personal regimen. 3
Safety & status
Injection-site reactions are common. Throat swelling requires urgent attention even when prescribed treatment is available; training and an individual emergency plan remain important. 3
Country and product status
This introduction describes the molecule and its research context. Product availability, approved indications and eligibility in Germany and Switzerland require a current local product check; they are not established by an overseas study or an online listing.
Frequently asked questions
Does it prevent the underlying inherited condition?
No. It treats an acute episode without removing the underlying tendency to attacks.
Can prescribed treatment replace urgent care for throat swelling?
No. Airway swelling remains potentially life-threatening and needs urgent medical attention. 3
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Icatibant: paper 10.1016/j.anai.2011.08.015 Research reference · Retained archive reference; not independently checked for this draft.
- Icatibant: ndclist.com reference Reference or product information · Retained archive reference; not independently checked for this draft.
- EMA: Firazyr European public assessment report Regulatory reference · EMA overview independently checked for indication, mechanism and clinical evidence; this is not a personal treatment recommendation.
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.